The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine.

Antipsychotic Agents / administration & dosage Binding Sites / drug effects ERG1 Potassium Channel / antagonists & inhibitors Erythromycin / administration & dosage HEK293 Cells Histamine H1 Antagonists, Non-Sedating / administration & dosage Humans Inhibitory Concentration 50 Macrolides / administration & dosage Patch-Clamp Techniques Terfenadine / administration & dosage Thioridazine / administration & dosage
BeKm-1 allosteric interaction erythromycin hERG long QT potassium channel

Journal

Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800

Informations de publication

Date de publication:
03 2020
Historique:
received: 18 12 2019
revised: 07 02 2020
accepted: 10 02 2020
entrez: 10 3 2020
pubmed: 10 3 2020
medline: 29 1 2021
Statut: ppublish

Résumé

The macrolide antibiotic erythromycin has been associated with QT interval prolongation and inhibition of the hERG-encoded channels responsible for the rapid delayed rectifier K

Identifiants

DOI: 10.14814/phy2.14385 PMID: 32147975 PMC: PMC7061092
pubmed: 32147975
doi: 10.14814/phy2.14385
pmc: PMC7061092
doi:

Substances chimiques

Antipsychotic Agents 0
ERG1 Potassium Channel 0
Histamine H1 Antagonists, Non-Sedating 0
KCNH2 protein, human 0
Macrolides 0
Erythromycin 63937KV33D
Terfenadine 7BA5G9Y06Q
Thioridazine N3D6TG58NI

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14385

Subventions

Organisme : British Heart Foundation
ID : PG/17/89/33414
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.

Références

Br J Pharmacol. 2003 Jul;139(5):887-98
pubmed: 12839862
Biochim Biophys Acta. 2011 Oct;1808(10):2477-87
pubmed: 21777565
J Mol Cell Cardiol. 2012 Jan;52(1):185-95
pubmed: 21989164
J Biol Chem. 2009 Jan 9;284(2):1000-8
pubmed: 18996846
Heart. 2003 Nov;89(11):1363-72
pubmed: 14594906
Biophys J. 2007 May 15;92(10):3524-40
pubmed: 17293393
Biochem Biophys Res Commun. 2005 Aug 26;334(2):441-9
pubmed: 16011830
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Pflugers Arch. 1996 Sep;432(5):930-7
pubmed: 8772145
Nature. 2006 Mar 23;440(7083):463-9
pubmed: 16554806
Cardiovasc Res. 2001 Mar;49(4):790-7
pubmed: 11230978
Proteins. 2007 Aug 1;68(2):568-80
pubmed: 17444521
J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):115-22
pubmed: 15922632
J Pharmacol Toxicol Methods. 2007 Sep-Oct;56(2):145-58
pubmed: 17590357
Biophys J. 1998 Jan;74(1):230-41
pubmed: 9449325
Psychosomatics. 2004 Sep-Oct;45(5):371-7
pubmed: 15345781
J Cardiovasc Pharmacol. 2008 Jun;51(6):549-52
pubmed: 18475200
Ann Pharmacother. 1994 Feb;28(2):282
pubmed: 8173153
Mol Pharmacol. 2000 Feb;57(2):367-74
pubmed: 10648647
Trends Pharmacol Sci. 2001 May;22(5):240-6
pubmed: 11339975
Am J Emerg Med. 1994 Nov;12(6):636-8
pubmed: 7945604
J Pharmacol Exp Ther. 2002 Jul;302(1):320-7
pubmed: 12065733
J Appl Toxicol. 2018 Apr;38(4):450-458
pubmed: 29143966
Pharmacol Ther. 2008 Aug;119(2):118-32
pubmed: 18616963
Eur J Pharmacol. 2013 Oct 15;718(1-3):87-97
pubmed: 24041920
Circ Res. 2002 May 3;90(8):889-96
pubmed: 11988490
Toxicol Sci. 2010 Apr;114(2):346-55
pubmed: 20071423
Am J Physiol. 1991 Feb;260(2 Pt 2):H393-9
pubmed: 1899980
FEBS Lett. 2003 Jul 17;547(1-3):20-6
pubmed: 12860380
Br J Pharmacol. 2000 Aug;130(8):1967-75
pubmed: 10952689
J Mol Cell Cardiol. 2004 May;36(5):701-5
pubmed: 15135665
J Biol Chem. 2002 Jun 28;277(26):23587-95
pubmed: 11960982
Pain. 2003 Oct;105(3):499-506
pubmed: 14527710
J Pharm Sci. 2011 Jun;100(6):2469-81
pubmed: 21491454
FEBS Lett. 2006 Apr 3;580(8):1999-2005
pubmed: 16542653
Mol Pharmacol. 2008 Nov;74(5):1443-52
pubmed: 18701618
Biochem Biophys Res Commun. 2006 Mar 10;341(2):500-6
pubmed: 16446155
Trop Med Parasitol. 1994 Jun;45(2):83-6
pubmed: 7939166
Cardiovasc Res. 2004 Apr 1;62(1):9-33
pubmed: 15023549
Br J Pharmacol. 2003 Jul;139(5):883-4
pubmed: 12839860
Physiol Rep. 2020 Mar;8(5):e14385
pubmed: 32147975
Br J Pharmacol. 2014 Apr;171(7):1668-75
pubmed: 24417241
Biochem Biophys Res Commun. 2006 Dec 8;351(1):273-80
pubmed: 17056009
J Pharmacol Pharmacother. 2013 Apr;4(2):116-24
pubmed: 23759957
Ther Adv Infect Dis. 2014 Apr;2(2):47-59
pubmed: 25165555
Mol Cell Biochem. 2003 Dec;254(1-2):1-7
pubmed: 14674677
Br J Pharmacol. 2007 Aug;151(8):1368-76
pubmed: 17592502
J Pharmacol Exp Ther. 2000 Jan;292(1):261-4
pubmed: 10604956
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):178-91
pubmed: 20172036
Cell. 1995 Apr 21;81(2):299-307
pubmed: 7736582

Auteurs

Aziza El Harchi (A)

School of Physiology and Pharmacology and Neuroscience, Biomedical Sciences Building, The University of Bristol, University Walk, Bristol, UK.
ORCID: 0000-0003-3329-6234

Andrew S Butler (AS)

School of Physiology and Pharmacology and Neuroscience, Biomedical Sciences Building, The University of Bristol, University Walk, Bristol, UK.
ORCID: 0000-0003-4362-940X

Yihong Zhang (Y)

School of Physiology and Pharmacology and Neuroscience, Biomedical Sciences Building, The University of Bristol, University Walk, Bristol, UK.

Christopher E Dempsey (CE)

School of Biochemistry, Biomedical Sciences Building, The University of Bristol, University Walk, Bristol, UK.
ORCID: 0000-0002-1933-7805

Jules C Hancox (JC)

School of Physiology and Pharmacology and Neuroscience, Biomedical Sciences Building, The University of Bristol, University Walk, Bristol, UK.
ORCID: 0000-0002-2055-6482

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Tranquillisants › Neuroleptiques › The macrolide drug erythromycin does not...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › The macrolide drug erythromycin does not...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Canaux ioniques › Canaux potassiques › Canaux potassiques voltage-dépendants › Canaux potassiques éther-à-go-go › Canal potassique ERG1 › The macrolide drug erythromycin does not...
questionsmedicales.fr › Composés chimiques organiques › Lactones › Érythromycine › The macrolide drug erythromycin does not...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › The macrolide drug erythromycin does not...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents histaminiques › Antihistaminiques › Antihistaminiques des récepteurs H1 › Antihistaminiques H1 non sédatifs › The macrolide drug erythromycin does not...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The macrolide drug erythromycin does not...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Concentration inhibitrice 50 › The macrolide drug erythromycin does not...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Polycétides › Macrolides › The macrolide drug erythromycin does not...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Techniques de patch-clamp › The macrolide drug erythromycin does not...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Terfénadine › The macrolide drug erythromycin does not...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques 3 noyaux › Phénothiazines › Thioridazine › The macrolide drug erythromycin does not...